TSVT vs. TYRA, OCUL, ABVX, SPRY, IMNM, IRON, CNTA, CVAC, ARCT, and ETNB
Should you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Tyra Biosciences (TYRA), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Disc Medicine (IRON), Centessa Pharmaceuticals (CNTA), CureVac (CVAC), Arcturus Therapeutics (ARCT), and 89bio (ETNB). These companies are all part of the "pharmaceutical preparations" industry.
Tyra Biosciences (NASDAQ:TYRA) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
Tyra Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500.
Tyra Biosciences currently has a consensus target price of $23.50, suggesting a potential upside of 44.88%. 2seventy bio has a consensus target price of $12.86, suggesting a potential upside of 203.95%. Given Tyra Biosciences' higher possible upside, analysts clearly believe 2seventy bio is more favorable than Tyra Biosciences.
In the previous week, Tyra Biosciences had 4 more articles in the media than 2seventy bio. MarketBeat recorded 5 mentions for Tyra Biosciences and 1 mentions for 2seventy bio. Tyra Biosciences' average media sentiment score of 1.89 beat 2seventy bio's score of 1.28 indicating that 2seventy bio is being referred to more favorably in the news media.
Tyra Biosciences has higher earnings, but lower revenue than 2seventy bio. Tyra Biosciences is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
2seventy bio received 7 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 62.07% of users gave Tyra Biosciences an outperform vote while only 60.98% of users gave 2seventy bio an outperform vote.
Tyra Biosciences has a net margin of 0.00% compared to Tyra Biosciences' net margin of -313.51%. 2seventy bio's return on equity of -28.61% beat Tyra Biosciences' return on equity.
84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 93.9% of 2seventy bio shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by insiders. Comparatively, 7.2% of 2seventy bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Tyra Biosciences and 2seventy bio tied by winning 9 of the 18 factors compared between the two stocks.
Get 2seventy bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
2seventy bio Competitors List
Related Companies and Tools
